21:33:53 EST Sat 16 Dec 2017
Enter Symbol
or Name
USA
CA



Amorfix Life Sciences Ltd
Symbol C : AMF
Shares Issued 69,074,623
Close 2015-07-06 C$ 0.04
Recent Sedar Documents

Amorfix investor acquires 12.27 million company shares

2015-07-07 19:18 ET - News Release

Mr. Michael Bigger reports

MICHAEL BIGGER DISCLOSES HIS POSITION IN AMORFIX LIFE SCIENCES

Michael Bigger has acquired, through a private placement offering with Amorfix Life Sciences Ltd., beneficial ownership, control and direction over 6,136,250 common shares of Amorfix and control and direction over an additional 6,136,250 common shares of Amorfix, at a price of three cents per acquired share, representing approximately 10.3 per cent of the issued and outstanding common shares, on a partially diluted basis, of Amorfix.

After giving effect to the private placement transaction, Mr. Bigger beneficially owns, controls or directs, directly and indirectly, 12,272,500 common shares of Amorfix, representing approximately 10.3 per cent of the issued and outstanding common shares, on a partially diluted basis, of Amorfix.

The acquired shares were acquired for investment purposes. Mr. Bigger may dispose of his holdings or acquire ownership of, or control or direction over, additional securities of Amorfix, depending on market conditions and in compliance with applicable law. The acquired shares were acquired pursuant to Section 2.3 of National Instrument 45-106 (prospectus exemptions) as the subscribers satisfy the definition of accredited investors under securities legislation.

The issuance of this news release is not an admission that an entity named in this news release owns or controls any described securities or is a joint actor with another named entity. A report with respect to the acquisition of the acquired shares will be electronically filed and will be available for viewing through the Internet at the Canadian System for Electronic Document Analysis and Retrieval.

Mr. Bigger's address is 159 Jennings Rd., Cold Spring Harbor, N.Y., 11724.

© 2017 Canjex Publishing Ltd. All rights reserved.